Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/srep33226.pdf
Reference21 articles.
1. Marie, I. et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47, 614–622 (2002).
2. Sontheimer, R. D. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositissine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46, 626–636 (2002).
3. Sakamoto, N. et al. Nonspecific interstitialpneumonia with poor prognosis associated with amyopathic dermatomyositis. Intern Med 43, 838–842 (2004).
4. Yokoyama, T. et al. Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes. J Intensive Care Med 20, 160–163 (2005).
5. Ye, S. et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: A retrospective cohort study. Clin Rheumatol 26, 1647–1654 (2007).
Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases;Arthritis & Rheumatology;2024-07-08
2. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases;Arthritis Care & Research;2024-07-08
3. Pirfenidone use in fibrotic diseases: What do we know so far?;Immunity, Inflammation and Disease;2024-07
4. Upfront combination therapy in anti‐melanoma differentiation‐associated gene 5 (MDA5) associated rapidly progressive interstitial lung disease;International Journal of Rheumatic Diseases;2024-06
5. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows;Pharmaceuticals;2024-05-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3